PRECISION BIOSCIENCES INC (DTIL)

Precision BioSciences Announces Late-Breaking Poster Presentation at the European Association for Study of the Liver (EASL) Congress 2024

Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics

DTIL Stock Earnings: Precision BioSciences Misses EPS, Misses Revenue for Q4 2023

DTIL stock results show that Precision BioSciences missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.

DTIL Stock Earnings: Precision BioSciences Misses EPS, Misses Revenue for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Precision BioSciences (NASDAQ:DTIL) just reported results for the fourth quarte...

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2023 Results on March 27, 2024

Precision BioSciences Presents Preclinical Data Highlighting PBGENE-PMM as a Potential Therapy for Primary Mitochondrial Myopathy

Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

Pre-market stock movers are worth checking on Friday as investors prepare for the last day of trading this week with all of the latest news!

Precision BioSciences stock falls after pricing $40M securities offering (NASDAQ:DTIL)

Precision BioSciences (DTIL) experiences a 16% premarket drop as it prices its securities offering to raise $40M, comprising common stock and warrants.

Precision BioSciences Announces $40.0 Million Offering of Common Stock and Warrants

Precision BioSciences Announces Proposed Public Offering of Common Stock and Warrants

Precision BioSciences Announces Non-Exclusive Patent License Agreement with Caribou Biosciences

Precision BioSciences Receives Pre-IND Feedback from US FDA for PBGENE-HBV as it Advances Towards Clinical Readiness

Precision BioSciences Promotes Naresh Tanna to Vice President of Investor Relations

Precision BioSciences Receives Initial $7.5 Million Cash Payment and Equity Investment from TG Therapeutics for Azel-Cel in Treatment of Autoimmune Diseases

Precision Biosciences to effect a reverse stock split (NASDAQ:DTIL)

vchal/iStock via Getty Images Precision BioSciences (NASDAQ:DTIL) Friday announced that its Board of Directors has approved a 1-for-30 reverse stock split...

Precision BioSciences to Effect a Reverse Stock Split

Precision BioSciences Completes License Deal with TG Therapeutics for Cell Therapy Azer-Cel in Treatment of Autoimmune Diseases

Precision BioSciences Announces Approval of First Clinical Trial Application of ARCUS Gene Insertion Program by Partner iECURE

Precision BioSciences Announces Publication in Nature Metabolism Supporting ARCUS® In Vivo Gene Editing as a Potentially Curative Treatment for Mitochondrial Diseases

Precision BioSciences to Present at Hep-DART 2023

Precision BioSciences Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Gene editing stocks mixed despite world’s first CRISPR drug

Gene editing stocks were mixed even after CRISPR Therapeutics (CRSP) and Vertex Pharma (VRTX), in a world's first, won U.K. nod for a CRISPR-based drug. Read more here.

Precision BioSciences Presents Late-Breaking Data Highlighting Preclinical Efficacy and Safety of PBGENE-HBV for Chronic Hepatitis B at AASLD’s The Liver Meeting 2023

Precision BioSciences to Present at Upcoming Sidoti Conference

Precision BioSciences Announces Late-Breaking Poster Presentation at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting